Literature DB >> 7053705

Hepatic veno-occlusive disease caused by 6-thioguanine.

R A Gill, G R Onstad, J M Cardamone, D C Maneval, H W Sumner.   

Abstract

Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine. Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement. Although this disease was clinically reversible, some subintimal fibrosis about the terminal hepatic veins persisted. This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7053705     DOI： 10.7326/0003-4819-96-1-58

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


  9 in total

1.  Peliosis hepatis induced by 6-thioguanine administration.

Authors:  D Larrey; E Fréneaux; A Berson; G Babany; C Degott; D Valla; D Pessayre; J P Benhamou
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

Review 2.  Intestinal and liver toxicity of antineoplastic drugs.

Authors:  G B McDonald; N Tirumali
Journal:  West J Med       Date:  1984-02

3.  Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.

Authors:  Linda C Stork; Yousif Matloub; Emmett Broxson; Mei La; Rochelle Yanofsky; Harland Sather; Ray Hutchinson; Nyla A Heerema; April D Sorrell; Margaret Masterson; Archie Bleyer; Paul S Gaynon
Journal:  Blood       Date:  2010-02-01       Impact factor: 22.113

4.  A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.

Authors:  Alexander Teml; Matthias Schwab; Daan W Hommes; Sven Almer; Milan Lukas; Thomas Feichtenschlager; Timothy Florin; Julia Seiderer; Wolfgang Petritsch; Bernd Bokemeyer; Wolfgang Kreisel; Klaus R Herrlinger; Peter Knoflach; Bruno Bonaz; Thomas Klugmann; Hans Herfarth; Nikolaus Pedarnig; Walter Reinisch
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

5.  Hepatic vein lesions in alcoholic liver disease: retrospective biopsy and necropsy study.

Authors:  A D Burt; R N MacSween
Journal:  J Clin Pathol       Date:  1986-01       Impact factor: 3.411

Review 6.  Drug effects on the liver. An updated tabular compilation of drugs and drug-related hepatic diseases.

Authors:  J Ludwig; R Axelsen
Journal:  Dig Dis Sci       Date:  1983-07       Impact factor: 3.199

7.  The possibility of using shogaol for treatment of ulcerative colitis.

Authors:  Snur Ma Hassan; Ali Hussein Hassan
Journal:  Iran J Basic Med Sci       Date:  2018-09       Impact factor: 2.699

8.  Indol-3-Carbinol and Quercetin Ameliorate Chronic DSS-Induced Colitis in C57BL/6 Mice by AhR-Mediated Anti-Inflammatory Mechanisms.

Authors:  Sina Riemschneider; Maximilian Hoffmann; Ulla Slanina; Klaus Weber; Sunna Hauschildt; Jörg Lehmann
Journal:  Int J Environ Res Public Health       Date:  2021-02-25       Impact factor: 3.390

Review 9.  The recent advancement of low-dimensional nanostructured materials for drug delivery and drug sensing application: A brief review.

Authors:  Hamidur Rahman; Md Rakib Hossain; Tahmina Ferdous
Journal:  J Mol Liq       Date:  2020-09-30       Impact factor: 6.165
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.